ArticleClinical genitourinary cancer2026
Outcomes for Patients With SPOP Mutated Castration-Resistant Prostate Cancer (CRPC) Treated With an Androgen Receptor Pathway Inhibitor (ARPI).
Article in Clinical genitourinary cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
introductionInactivating missense mutations in the SPOP gene increase the transcriptional activity of the androgen receptor and sensitivity to hormonal therapies in patients with hormone sensitive prostate cancer (HSPC). However, the relationship of SPOP alterations with differential outcomes by race, particularly in patients with castration-resistant prostate cancer (CRPC), remains unclear. PATIENTS AND
methodsWe conducted a retrospective case-control analysis of 78 SPOP-mutated (SPOPmut) patients matched to 223 SPOP wild-type (SPOPwt) patients who received first-line ARPI therapy in the CRPC setting. All patients had somatic gene profiling using the Tempus xT or xF NGS assays. We compared PSA declines, time to treatment failure (TTF), progression-free survival (PFS), and overall survival (OS) with ARPI treatment by race and SPOP status.
resultsWe identified SPOP mutations in 29% of Black men (n = 10/34) and 20% of White men (n = 30/150). After adjusting for race, visceral metastases, PSA, and M1 at diagnosis, there was no significant difference in TTF (HR 0.80, 95% CI, 0.56-1.15, P = .2), PFS (HR 0.81, 95% CI, 0.58-1.12, P = .2) or OS (HR 0.81, 95% CI, 0.55-1.19, P = .3) by SPOP status. Black men had improved OS with first line ARPI in the CRPC setting (HR 0.44, 95% CI, 0.24-0.79, P = .006) irrespective of SPOP status. PSA declines were more common in SPOPmut patients, with a PSA90 decline in 51% versus 31% (OR 2.35, 95% CI, 1.09-5.12). SPOP mutations were associated with AR ligand-binding domain mutations, APC, and CDKN1B alterations in CRPC.
conclusionIn this exploratory analysis, we found that Black men have improved survival in the first line mCRPC setting with ARPI therapy, but that SPOP mutations do not explain these differential outcomes despite improved short term PSA declines. Thus, other factors may explain the disparity in outcomes we confirmed in men with CRPC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.